You are here: Industry Insights > Agendia

News List

MammaPrint® Becomes Only Molecular Diagnostic Recommended for Early-Stage Node-Positive Breast Cancer Patients in ASCO-Endorsed Cancer Care b3cnewswire
June 27, 2019
MammaPrint® Becomes Only Molecular Diagnostic Recommended for Early-Stage Node-Positive Breast Cancer Patients in ASCO-Endorsed Cancer Care Ontario Guidelines.
Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology b3cnewswire
June 21, 2019
Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology.
Agendia and Imegen Announce an Exclusive Distribution Agreement for MammaPrint® and BluePrint® in Spain and Portugal b3cnewswire
May 22, 2019
Agendia and Imegen Announce an Exclusive Distribution Agreement for MammaPrint® and BluePrint® in Spain and Portugal.
Agendia and Angsana to Provide Breast Cancer Risk-of-Recurrence Testing with MammaPrint® and BluePrint® to Patients in Southeast Asia b3cnewswire.
June 04, 2018
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, and Angsana Molecular & Diagnostics Laboratory Pte Ltd, a subsidiary of Parkway Pantai
Agendia Announces CE Mark for NGS-Based MammaPrint® BluePrint® Kit Enhancing Access to Personalized b3cnewswire
March 22, 2018
Agendia, Inc., today announces that its next-generation sequencing -based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit is now CE marked, enabling the Company to commercialize the device in Europe.
Agendia Collaborates with Prestigious Cancer Center, Institut Curie, for MammaPrint® BluePrint® Brea b3cnewswire
December 06, 2017
Institut Curie is one of an increasing number of major European cancer centers to become a co-validation partner for the new NGS-based MammaPrint BluePrint Kit
Agendia Appoints Patrick J. Balthrop Sr., Former CEO of Luminex, as Chairman b3cnewswire
April 14, 2017
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces the appointment of Patrick J. Balthrop Sr., former CEO of Luminex, as Non-Executive Chairman.
Agendia Appoints Patrick J. Balthrop Sr. as Chairman americanpharmaceuticalreview
April 14, 2017
Agendia, Inc. has announced the appointment of Patrick J. Balthrop Sr., former CEO of Luminex, as Non-Executive Chairman.
European Group on Tumour Markers (EGTM) Updated Guidelines Recommend Agendia’s MammaPrint® Test with b3cnewswire
March 22, 2017
Agendia, a world leader in personalized medicine and molecular cancer diagnostics, announces that updated guidelines from the European Group on Tumour Markers (EGTM).
Agendia Co-Founder Laura van ’t Veer Wins European Cancer Organization Clinical Research Award b3cnewswire
February 07, 2017
Significant clinical benefit of Agendia’s MammaPrint® test and other advances in the improved treatment of breast cancer recognized at ceremony during ECCO2017